Please assess the completion status of the following clinical trial:

Trial Title: S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed urothelial cancer~  * Transitional cell carcinoma, adenocarcinoma, or squamous carcinoma (bladder, renal pelvis, ureter, or urethra)~* Previously untreated metastatic or locoregionally advanced (i.e., bulky pelvic nodes) disease OR~* Locally recurrent carcinoma after radiotherapy or cystectomy and no longer eligible for further radiotherapy or surgery~* Measurable disease~PATIENT CHARACTERISTICS:~Age:~* 70 and over OR~* Under 60~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,200/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than upper limit of normal (ULN)~* Aspartate aminotransferase (SGOT) or alanine aminotransferase (SGPT) no greater than 2 times ULN~Renal:~* Creatinine no greater than ULN~Other:~* HIV negative~* No other concurrent life-threatening medical disorder that would preclude study participation~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Prior adjuvant chemotherapy is allowed provided administered more than 10 years ago~* No prior gemcitabine, taxanes, or platinum-based adjuvant chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* At least 28 days since prior radiotherapy and recovered~Surgery:~* See Disease Characteristics~* At least 28 days since prior surgery and recovered

- Gender: ALL
- Minimum Age: None
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- gemcitabine, paclitaxel (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).